endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

Gala­pa­gos CEO Paul Stof­fels to step down, for­mer Neumo­ra chief to lead spin­out

Last month
People

In­sur­ers have a Medicare Ad­van­tage prob­lem

Last month
Health Tech

Dana­her ex­pects about $350M in tar­iff costs; Alu­mis, Ace­lyrin ad­just deal terms

Last month
News Briefing

Ex­clu­sive: George Church start­up will study long-lived an­i­mals, hu­mans to find life-ex­tend­ing genes

Last month
Financing
Startups

Drug­mak­ers stock­pile in­ven­to­ry in the US, seek­ing to get ahead of Trump tar­iffs

Last month
China
Pharma

Pre­ven­tive health start­up Su­per­pow­er rais­es $30M

Last month
Financing
Health Tech

As the XBI suf­fers, Q1 shows a few com­fort­ing signs of un­der­ly­ing sta­bil­i­ty

Last month
Bioregnum

Up­dat­ed: Roche’s $50B US in­vest­ment in­cludes pre­vi­ous build an­nounce­ments

Last month
Pharma
Manufacturing

As­traZeneca, Dai­ichi eye first-line breast can­cer mar­ket af­ter En­her­tu's ear­ly Phase 3 win

Last month
R&D
Pharma

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

Last month
FDA+

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Last month
FDA+

Alvo­gen unit ap­peals court loss shield­ing Bausch Health's IBS drug from gener­ics

Last month
Pharma
FDA+

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Last month
Startups
R&D

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Last month
R&D

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

Last month
People
R&D

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

Last month
FDA+

Trump’s ex­ec­u­tive or­der on drug pric­ing; Pfiz­er drops oral obe­si­ty drug; Seed rounds at their low­est in years; and ...

Last month
Weekly

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

Last month
Startups
Deals

GSK kicks off Blenrep re­launch plans with clear­ance from UK reg­u­la­tors

Last month
Pharma
FDA+

CMS would ab­sorb 340B drug dis­count pro­gram un­der leaked HHS re­or­ga­ni­za­tion pro­pos­al

Last month
Pharma
FDA+

Roche dis­con­tin­ues low dose in Hunt­ing­ton’s tri­al, will switch pa­tients to high dose

Last month
R&D

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Last month
Pharma
Manufacturing

What it took for Wal­greens to go pri­vate

Last month
Health Tech

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Last month
Deals
First page Previous page 16171819202122 Next page Last page
A service from the Financial Times